Global Non-Alcoholic Steatohepatitis Biomarkers Market Size and Forecast 2024-2033|Genfit SA, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics

The Non-Alcoholic Steatohepatitis Biomarkers by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Non-Alcoholic Steatohepatitis Biomarkers Market:

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-biomarkers-global-market-report

According to The Business Research Company’s Non-Alcoholic Steatohepatitis Biomarkers, The non-alcoholic steatohepatitis biomarkers market size has grown exponentially in recent years. It will grow from $1.11 billion in 2023 to $1.39 billion in 2024 at a compound annual growth rate (CAGR) of 25.6%. The growth in the historic period can be attributed to diabetes and metabolic syndrom, awareness and screening programs, liver biopsy limitations, regulatory support, shift towards personalized medicine, clinical trials in nash..

The non-alcoholic steatohepatitis biomarkers market size is expected to see exponential growth in the next few years. It will grow to $3.2 billion in 2028 at a compound annual growth rate (CAGR) of 23.1%. The growth in the forecast period can be attributed to emergence of novel therapies, expansion of precision medicine approaches, patient advocacy initiatives, integration of multi-omics data, enhanced patient engagement.. Major trends in the forecast period include telemedicine and remote monitoring, innovative diagnostic platforms, global collaborations in research, technological advancements in biomarker discovery, integration of artificial intelligence (ai), inclusion of imaging biomarkers.

The growing prevalence of liver cancer is expected to propel the growth of the non-alcoholic steatohepatitis biomarkers market going forward. Liver cancer refers to the development of malignant tumors within the liver and can start in the liver itself (primary liver cancer) or spread to the liver from other parts of the body (secondary or metastatic liver cancer). Non-alcoholic steatohepatitis (NASH) biomarkers are used in liver cancer for early detection, disease progression monitoring, and treatment response assessment, to provide prognostic information, and can help reduce the need for invasive procedures. For instance, in October 2022, according to the Journal of Hepatology, a Switzerland-based medical journal that primarily focuses on hepatology, according to recent studies, hepatitis B virus (HBV) is thought to be responsible for about 56% of liver cancer cases. Therefore, the growing prevalence of liver cancer is driving the growth of the non-alcoholic steatohepatitis biomarkers market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=9002&type=smp

The non-alcoholic steatohepatitis biomarkers market covered in this report is segmented –

1) By Type: Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types

2) By Disease: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity

3) By End Use: Research Institutes And Academics, Diagnostic Centres, Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs), Hospitals And Clinics, Other End-Uses

Technological advancements are a key trend in gaining popularity in the non-alcoholic steatohepatitis biomarkers market. Major companies operating in the non-alcoholic steatohepatitis biomarkers market are focused on developing innovative solutions to strengthen their position in the market. For instance, in October 2022, GENFIT, a France-based late-stage biopharmaceutical company, and LabCorp, a US-based life sciences company, agreed on a five-year exclusive licensing deal for GENFIT’s NIS4 technology to aid in identifying patients with non-alcoholic-steatohepatitis-at-risk (NASH). NIS4 technology is an innovative, multi-biomarker-based algorithm specifically developed to identify patients with non-alcoholic steatohepatitis (NASH) and significant to advanced fibrosis (F > 2), also referred to as at-risk NASH. As part of the agreement, LabCorp will develop and commercialize a blood-based molecular diagnostic test utilizing NIS4 technology in the United States and Canada, giving widespread access to healthcare professionals.

The non-alcoholic steatohepatitis biomarkers market report table of contents includes:

1. Executive Summary

2. Non-Alcoholic Steatohepatitis Biomarkers Market Characteristics

3. Non-Alcoholic Steatohepatitis Biomarkers Market Trends And Strategies

4. Non-Alcoholic Steatohepatitis Biomarkers Market – Macro Economic Scenario

5. Global Non-Alcoholic Steatohepatitis Biomarkers Market Size and Growth

26. South America Non-Alcoholic Steatohepatitis Biomarkers Market

27. Brazil Non-Alcoholic Steatohepatitis Biomarkers Market

28. Middle East Non-Alcoholic Steatohepatitis Biomarkers Market

29. Africa Non-Alcoholic Steatohepatitis Biomarkers Market

30. Non-Alcoholic Steatohepatitis Biomarkers Market Competitive Landscape And Company Profiles

Top Major Players: